Hard hitting medical truth,
cutting through conflict and confusion to the understanding
you're searching for.
Join doctor Peter McCullough,
world renowned medical expert and practicing physician, for
this edition of the McCullough Report.
Your life may depend on it.
Let's get real. Let's get loud on America.
Talk radio. This is a McCullough Report and
courageous discourse subject. I'm doctor Peter McCullough, president
of the McCullough Foundation.
And it's my great pleasure to welcome to
the show, doctor John Catanzaro.
And, man, he has a background,
and he's got some red hot ideas. And,
you know, we've been looking for
people in the biotech space
to help us navigate
through this really difficult time where 75% of
Americans took a a a COVID 19 vaccine.
Of those,
94% took a messenger RNA vaccine. So the
for the first time, they took some foreign
RNA in their body. John, welcome to the
show. Thank you so much for joining.
Thank you, Peter. Thank you for having me
on. Appreciate that so much.
Tell us a little bit about your background.
Yeah.
My my background is,
kinda long.
My original,
delve into technology was in the aerospace industry,
and then
saw my second career was moving into,
integrative medicine. So I I was,
you know, graduate of Bastyr University
and, worked in integrative oncology for about 25
years, and so I worked with a lot
of resistant illnesses.
And then I retired in 2017
and started Neo 7 Bioscience, a biotech company
that specifically focuses in on personalized precision therapeutic
development.
And I am the cofounder and the CEO
of this company.
It's privately held, and,
and so
just wanted people to know that,
this is, this is what our company does.
And, basically, it,
through the whole process,
I don't
my work in,
in molecular,
genetics,
as well as proteomics and
working with,
you know, peptide engineering,
had allowed me to,
integrate that into,
practice with with patients for for that, you
know, almost 25 years, as I mentioned. And
so we were able to collect a lot
of data,
through those years. We made a a lot
of headway with,
many patients with resistant cancers and resistant illnesses,
and we were able to,
make a significant mark in,
life extension, quality of life,
and helping people to recover from pretty devastating
illnesses,
using these,
type of personalizations.
So with
that, in our expansion into Neo7 Bioscience, because
we've actually had opportunity to look at a
lot of patient data,
we have come across many type of resistant
illnesses, including cancer,
that have a strong association
with,
the mRNA
spike protein,
and also,
segments of mRNA
influencing
ribosomal shifting,
and pretty much corrupting transcription translation,
type activity, which cause causes more of, aberrant
type molecular signals. So we get to see
these aberrant molecular signals very plainly in the
molecular data of the patients.
So now we've been able we've been able
to compare,
some significant,
data data sets of patients that have these
resistant illnesses, including cancer
and chronic inflammatory disease and people that have
been vaccinated with the COVID mRNA.
And we find that correlation very high. I
mean, a a very a very prominent part
is when we see, RNA transcription amplification.
So we get to see some things like,
the
WNT pathways, the notch pathways. People,
you know, don't maybe may not understand everything
about what these pathways do, but they're cell
proliferating pathways. They actually cause cell cellular dysregulation,
which allow for a higher probability of excess
mutations to occur.
And we also see the DNA mismatch repair
proteins,
affected quite significantly.
And we also have been
looking really,
in detail with immune immune regulatory proteins
that are skewed,
in most patient data sets. So we get
to see immune regulation,
fault, you know, faulting,
a lot of the variant signals with these
proteins,
in association with, you know, with that mRNA
splice
type segment of the of the RNA.
Yeah. It doesn't look good.
But let's, let's try to fill out
this, your company,
and this whole idea of peptides.
So
some of our listeners are doctors or nurses,
but many are just the lay people.
You know, what is a peptide, and and
what do you mean by when you, you
know, give it therapeutically to a cancer patient?
You know, peptides are building blocks of proteins.
Basically, they're
formed by, an assembly of amino acids, and
those amino acids build the protein. Right?
And and our
our bodies actually have,
a significant number of functional proteins that keep
proper function of the body,
proper feedback of the body. So peptides are
very important elements in protein building,
and and they are the result
of
the things we're talking about,
gen genetic signaling,
DNA
movement into messenger RNA, you know, all the
stuff that I was mentioning about ribosomes,
frame shifting and stuff like that. All of
these all of these elements are important in
being able to
code
for those peptides to build in a in
a strong,
structural protein.
And what we see,
when these, proteins are affected in a negative
and adverse way, these proteins wind up having
points,
of,
shifting
to where we can see that the protein
structure on simulation is not as tightly bound
as it should be. So we get to
see a lot of different molecular
implications
when a protein is not healthy.
And in cancer,
what are the what's the roles of these,
aberrant proteins? Do they
foster tumor
growth or metastases?
Or, you know, what are they doing?
Yes. The aberrant proteins,
you know, as
in the cancer evolution,
affect things like tumor promoters, tumor suppressors,
tumor regulators. So a lot of these activities
that are happening that are driven by various
type of immune molecular signals,
we'll find that can corrupt the signal messages
that affect more tumor promoting activity,
the failure of tumor suppressor activity,
more high grade mutations to develop that actually
cause more migrational shifts,
in the cancer.
We see these correlations quite regularly with these,
when we're looking at these molecular
profiles.
So so when when these,
abnormal proteins are identified in cancer,
what is the therapeutic opportunity then?
Well, therapeutic
opportunity,
what we have,
developed anyway is we we take these molecular
high fault signals that we see in in
the evolution. So we do a very extensive,
interrogation
and prediction.
And in our interrogation and prediction,
we are able to locate the top high
ranking signal targets that are creating resistance in
the cancer evolution. So like in other words,
we'll take a look at it and we'll
say, okay. We we've got significant amount of
proteins that are that are based on hallmark
expressions of the cancer.
There are 15 known hallmarks currently,
and and
and we're seeing a lot more development to
where there's more hallmarks involved. But like for
instance, a good example of a hallmark is
dysregulated
immune function or tumor promoting or cell proliferation
or,
you know, DNA instability. There's a lot of
for,
very dysfunctional activity in the in the landscape
of the cancer.
And so what we could see is the
degree by which these proteins influence and how
they then affect their sister targets down the
line. So in other words, you can have
a
top level signal target that can influence
string,
sister relationship proteins that are also drivers in
the cancer evolution as well. So what we
do is we find the,
the the peptides that are direct,
influences that either will mitigate,
potentiate,
or regulate
those proteins
appropriately
and allow for signal changes in in expression
to assist with the ability to eradicate cancer.
Are these proteins
themselves, are they completely
unnecessary? I mean, if if one was to
take them out with a monoclonal antibody, would
would that be a a strategy, or do
you need some of them?
Well, you know, some of these proteins and
what we've been learning through our research is
we find that,
you know, these cancer expressions involve more than
one target. You know, in the conventional
community,
currently, what we see in research is that
we isolate one target. Like, for instance, if
you look at BRCA 1 and BRCA 2,
as, you know, very,
very fashionable targets.
Unfortunately, a lot of people are not aware
that BRCA is associated with the BRCA complex,
which actually influences about
15 or 20 other particular gene protein relationships.
Right?
So so the signaling is a cross signaling
relationship that happens across the board. So you
can never just say, oh, well, this bracket
is, you know, is the problem. And I
give you an example of that. When we
had a patient,
whose,
mother passed away from,
breast cancer and she was bracket 2 positive,
Then the sister was also BRCA 2 positive,
but the other sister was BRCA 2 negative,
which is the patient that we analyzed.
And what we found was she had a,
expressed protein
in the proteomics portion excreted in her urine,
and the BRCA 2 was positive in her
urine. So she did not have a mutation
in her main genomic dataset,
which but she had the disease related protein
being expressed in her urine, which is a
very hot biomarker. Right? So a lot of
the times, but, you know, you wind up
detecting these things,
by looking at the genomics, by looking the
transcriptomics, by looking at the proteomics, and by
looking at the patient's own HLA immunophenotype.
And when we actually see what their susceptibility
and compatibility is, these are important drivers
in being able to identify
how to get
more intelligent into that disease space to influence
it,
to allow for eradication
of that particular cancer or those cells or
the or that particular tumor. Right?
So are those proteins,
at least some of them also amenable to
be disease markers that you could measure to
see about progression of disease?
Absolutely. Absolutely. Yes. Yep. For sure.
So is it fair to say, you know,
there's been such a big focus on genetic
abnormalities in cancer that there's been a lesser
focus on proteomic or protein changes in cancer.
But what we're hearing from you is that
the protein changes,
boy, those look pretty good to study
as targets, whether they be with
interfering
or
modulating
proteins or monoclonal antibodies.
And also, we can you know, the nice
thing about proteins, most people know this, we
can measure them in blood. We can do
a blood sample, or we can measure them
in urine too,
and then assess for markers. So it sounds
like this is a pretty hot area. What
type of tech do you use
to,
examine
proteins and the library of proteins potentially
at play?
Excellent.
We we have high definition okay. So looking
at the complete picture, we do high high
definition omics,
which means high definite high definition genetics. And
what difference between high definition is that we're
not using shotgun shotgun type genetics where we're
just trying to create array profiles.
We're actually looking at high definition because the
whole idea is we have an engineering output.
So the engineering output is actually the personalized
therapeutic that's developed for the patient. Right? So
now when we're doing our proteomics, we're doing
excretion proteomics, which means we're capturing things in
the urine. We can actually capture 6,000 plus
proteins
in the urine. Not all of those proteins
are based on normal functional rhythms, but they're
actually based on disease expressions.
Right? So we we know which ones, in
our in our confidence mapping,
are specific to a disease type, not just
cancer, but we also see it in autoimmune
disease too.
And,
so it's pretty it's pretty amazing to see
it. So we the technology that we use
is an exosomal technology in our proteomics, so
it's a direct it actually uses direct and
indirect, and it also uses exosomal extraction
methods to be able to have a more
high definition on the proteins that are captured.
And,
and so we're we're we're,
you know, pretty excited about our technology that
way because we can get proteins that no
other institution can measure. And and what type
of detail can you get on these proteins
in terms of amino acid
and structure and,
you know,
carboxylation, methylation, oxidation,
glycosylation
of side chains. Can you get, like, a
really rich description of what this protein is?
Yes. We we actually get the full descriptions
of that. So we we'll we'll knowing, you
know, all about the chemistry of the protein,
you know, we're looking at the the polar
shifting of the protein. We're looking at how
it how it forms as a molecular SIM
model where you had seen whether or not
the protein has got, you know, intact structure.
Because when we study these proteins, we actually
have to look for the best peptide sequences
that are gonna bind into the pockets. Right?
So we are, you know, we're using a
very sophisticated technology to do it.
And is this type of,
modeling when, you know, we always hear about,
forms of modeling to try to model how
things would fit.
Are you finding that the models now are
sufficiently
predictive that when you go to all the
effort to actually create a peptide that it
works?
Yes. Yes.
And we say that confidently because we've seen
it work with, a lot of resistant cancer
to where cancer cases in stage 4 become
completely
disease free. No evidence of disease.
Wow. And we're we're also seeing it on,
like, for instance, so when we talk about
vaccine related injury,
where we act where we're seeing an excessive
amount of pro inflammatory activity on vasculature.
And, we just recently picked up,
an inoperable intracranial
aneurysm,
that was a direct cause of the COVID
vaccine,
type of injury.
And this patient had,
3 booster shots
of the COVID vaccine.
And so we actually just created a, intranasal
design for this patient that, he will be
starting pretty soon. But but the thing the
thing about this is is that when you
know what the signal targets are and what's
like, for instance, on his on his profile,
he had some very definite vascular vascular endothelial
dysfunction.
So that means that the capabilities of the
vascular remodeling couldn't happen, and there was a
lot of pro inflammatory activity,
direct,
directly
seen on that particular,
on his molecular expressions.
So when we actually looked at his datasets,
we,
you know, developed a mitigation
regulation strategy and an enhancement strategies to allow
for better vascular integrity,
which we believe would have a very good,
potential because he's he's got no other options.
He he's inoperable.
He's a ticking time bomb
and nothing else to do. So, we also
coupled that with, with, exosomes, which would allow
for the delivery to the targets that we
wanna see. So we're pretty excited about this,
but this is just an example of working
with,
vaccine related pro inflammatory
destructive proteins.
You know, we we you know as well
as I do the rope protein effect by
this frame shifting,
this ribosomal frame shifting, and the, you know,
open reading frame, you know, dysfunction that we
see.
And then this reincorporation
of mRNA
back into DNA by what we call a,
a, splice DNA movement
from the retrotranspose
in action and using reverse transcriptase. So we
actually see
these type of activities by these transcription
genes are
definitely positive.
So so the data does not lie. Let's
just say that. The data is very, very
pointed about showing us
these discrepancies.
Well, let me ask you just before we
leave cancer and we get on to the
vaccines because it sounds like you're really, you
know, heading in just to such a big
new field.
Are there peptide products that you can point
to
in oncology
that,
are standard issue right now, or,
is what you're describing in a sense
uniquely personalized to each individual?
Yes. It's,
you know, there are, peptides out there that
are known as the augmented,
anticancer
peptides.
There are many of them out there. Like,
for instance, there's a peptide out there called
PNC 27,
PNC 28. It's used in,
pancreatic cancers, but it also could be used
in some other cancers as well. It's got
a very strong
initiating outside the apoptosis movement or a pop
the apoptotic movement.
It it actually has a direct cell lysing
effect on the cancer cells without any toxic
effects or for surrounding cells. So that's a
that's a pretty well known,
anticancer
peptide.
But now when we talk about molecular personalizations,
it's end of 1. So that means that,
you know, you could have 2 people that
have the same exact cancer, but, and they
may have the same 2 similar targets, but
their peptide sequences to the target are dynamically
different. So, so that means they'll have a
different expression, and it's not just to elicit
t cell responses.
So a lot of the time, the literature
that's out there is kinda misleading because it's
giving you,
the it's giving you kinda like a condition
like, oh, we're just using them as fashionable
neoantigens
and and potentiating
activity against the cancer cells direct on discrepant
cell expressions like the tumor associated antigens.
But but the thing is is that they're
more than that. These these
personalized peptides
are actually
signal,
propagators.
So they they they work through a self
assembly activity. Once they're in the body and
they're properly scaffolds, they'll get into the interior
of the cell and begin to change programming,
not like mRNA,
because the the peptides will work from a
standpoint of facilitating a natural movement into a
better a a better relationship in the cell
machinery,
whereas mRNA has very very fast decay rate
and a very unpredictable rogue effect. So you
won't have that with a well assembled
personalized peptide.
Well, now peptides,
are we talking about,
oral or intravenous or both?
Mainly injectable,
intravenous,
subcutaneous, intramuscular,
or intranasal
because we also have intranasal deliveries as well.
And then what,
protects these peptides from just being,
slipped by, you know,
clipped by proteases, normal
human proteases that just will digest it?
It's the way that they're assembled. So, like,
our peptides are assembled by by creating what
we call cell linkage strategies
by putting, like,
a, a linkage strategy that allows for cell
penetration. So we have, you know, proprietary
linkage strategies that are put onto the sequences
that are dynamically matched to the, to the
molecular targets.
We also have what we call tumor penetration,
scaffolding, which allows for a better movement into
the tumor space. And we also have what
we call an aminohexaenoic
acid bridging, which allows for the flexibility of
the molecule so that it can be,
transported better. And then we also PEG ELATE.
So in other words, PEG ELATION allows just
small fractionated PEG that allows the the protein
to move to the target,
freely without it being hit by any, you
know, proteolytic
activity.
Okay. Now are they hue are they humanized
proteins,
or are they going to trip off immune
reactions to them itself?
Well, they they will, you know, they are
synthetically
manufactured
even though they're matched to the patient's targets.
Right? So they they are going to have
somewhat of an immunogenic
effect and a positive vantage point, not like
you would see with antibodies when antibodies are
coming in, and then you wind up getting
off target reactions from the antibodies. Right? So
you're not gonna see the same effect when
it's a personalized design that way.
You're gonna have very low risk of off
target reactions. You're going to have an immune
immunogenic
potentiation
specifically to activate the immune system in a
favorable fashion
rather than an
unfavorable fashion. And you're gonna have more of
a likely over
likelihood
to overcome
what you're seeing in the resistance of the
disease itself, because you're allowing for multiple targets
to work at the same time.
Well, do do patients,
in the research of this and
clinical application, do they ever need pretreatment with
antihistamines
or steroids, or are they pretty well accepted?
You know what? They're pretty well accepted, generally
speaking.
But there are times when there's there's also
a coupling for using, you know, dexamethasone
to to to create an ablative effect. Because
if you actually have an extreme amount of
pro inflammatory activity in a tumor microenvironment,
so you're going to have like a macrophage
difference of M1, M2
macrophage slimy layer of the tumor. And a
lot of cases when you combine it with
a, something like dexamethasone,
it actually creates an ablative effect to allow
the peptides to penetrate better.
So in those cases, it it's a very
good therapeutic,
accent. Right?
Now some patients that are hypersensitive,
they might need some, you know, antihistamines.
They might need a little bit of, you
know, steroids to kinda just calm the system
down a little bit, but very
So so when you have a patient let's
say I have a patient and I'm considering
this,
approach,
are blood and urine samples for the patient
enough? Or or does your lab and your
team do you actually need the tissue sample
of of the cancer?
Excellent question. The the blood and urine are
enough. So with the blood, what we're looking
at is we're looking at the the the
total the total exome,
the high these are all high definition now.
RNA transcriptome, we're looking at the expressions there.
We're looking at the optotype, which is the
molecular typing of the patient.
And, and then we're looking at the urine
as I was explaining earlier, a full complete,
urine,
proteomic
analysis.
Yep.
Now Now in in cases of, like, for
instance, I answer with tumor tissue, we also
do tumor tissue, but a lot of the
times the tumor tissue is inaccessible, hard to
get, very difficult.
A lot of times, institutions don't wanna turn
loose of it for various reasons that I
won't get into here. But but the thing
is is that, we don't we don't stop
at that because we don't need the tumor
tissue to tell us which way to go.
Well, it's also yes. It's so convenient for
the patient. Now does the company have products,
either FDA approved products or products that you
know, available, not subject to FDA approval?
The the product mainly that NeoCement Bioscience is
developing,
is is investigational experimental. Right? So it's all
operating under an IRB.
You know, it's not under a clinical trial,
so we don't have any NIH studies on
it, which all it's all IRB
practice oriented select. There's a lot of, physicians
that are neo 7 participating
physicians,
and they,
you know, they they are working with us
to to administer this to their patients.
And, so that's how we operate, you know,
at this point. Now in the future, we're
hoping to maybe
get a little bit more research out there,
and establish it, you know, more in the
research environment,
more publications.
But we've been real stealthy about how we
do it because we've been helping a lot
of people
over the last 4 years.
Now is the company
involved in these
big
cancer,
research centers like MD Anderson and
Sloan Kettering,
or
and or is the company working with, was
considered naturopathic
centers that, you know, are much different?
It's more integrative centers. So,
functional medicine centers, integrative cancer centers,
you know, that type of environment. And we're
not currently in any type of
MD Anderson or any other Mhmm. Larger organization.
I mean, I have patients come to me
and practice. I'm a traditional allopathic doctor. I
prescribe medicines, internal medicine, cardiology.
I've had so many cancer patients come to
me and say, doc, I'm just not gonna
do the conventional
chemo,
radiation
and surgery.
I had a patient recently who's just it's
just had a an incredible
tongue and throat cancer. In fact, I
examined
her, and I depressed the tongue, and the
cancer just flipped up into view. It was
just
astonishing to see it face to face.
And
and she's made up her mind. She says
it's inoperable. I'm not gonna go through
chemotherapy and radiation. And, John, I have to
tell you as a doctor, a non cancer
doctor, I always ask myself,
is the appearance of the patient
and their current illness?
Is it due to the cancer,
or is it due to the chemotherapy
radiation and other things that have happened? I
mean, the question does come up,
particularly for advanced cancers where the survival rate
is low.
What does a patient look at if they
go to a holistic or integrative center? Because
I know you work with these centers.
But what's your vantage point? What what's the
approach when a patient goes to one of
those centers?
Well, when they when they're going to an
integrative center, they're going to have the support,
you know, the immune support that's needed to
kinda really boost up their immune defenses. So
various physicians actually have different protocols where they'll
use intravenous vitamin C, they'll use, you know,
various type of intravenous bio homeopathic regulators.
They'll, you know, there's a lot of power
in, in some of the nutrients that are
out there
that are used intravenously.
And,
and when we're working with with these doctors,
we're adding
a level of sophistication as a
strategy. So what we say is that, you
know, you're not gonna be flying blind here.
You're gonna know exactly what you're doing with
regards to the molecular influences of this disease.
You're going to be able to intelligently hit
those targets by using the personalized engineering,
and you can couple any therapeutic with it.
So, like, even if a patient decided to
do radio you know, targeted radiation or,
you know, the proton therapy or, or something
like that. You know, it works really well
together
in being able to facilitate the anti
cancer activity,
but it also assists in being able to
help the tissue to recover better. So it
helps with more rejuvenation of the tissue.
And a lot of the times you're act
you know, you are so correct with regards
to when you're seeing the the cancer itself.
A lot of times these,
we do one step up you see in
the environment where they're going from chemo to
chemo to chemo, they go to a stronger
chemo. And what that happens is is it
it might work for 3 months and it
creates a stronger resistant pattern as you've probably
observed yourself, and then the cancer rages terribly.
Right? And I've seen that in all my
years practice too. It's a terrible thing to
watch. And, and but it's a very real
thing that happens. So the resistance is a
reality,
with some of these conventional therapeutics.
Wow.
Now are you able to disclose,
where some of the top centers with your
technology
available? Because my my my fans are gonna
ask. They're gonna say, listen, you know, can
you give us any referral center information?
Well, what we usually do is we, we
we share that information when they contact us
because, you know, we have different patients in
different locations,
and we do have centers that that are
you know, we have strategic areas where where
patients actually go. Okay. And we're and we're
growing, you know, more rapidly because of the
fact that this is you know, people are
really calling for this.
And and I'll just be honest here. It's
like it's not a cheap technology. Right? It's
a
it it is not something, you know, when
we're talking about sophisticated n of 1 personalizations,
I mean, it's a lot cheaper than using
traditional immunotherapy
or, you know, conventional immunotherapy or some of
these chemo strategies.
You know, but it it it it is
more of a high priced item,
going into it. And the thing about it
is that patients actually are paying out of
pocket, right? So it's not covered by insurances.
Though there are some patients that actually will
submit itemized bills from their physicians to insurances,
and some of them get up to maybe
35 to 50% coverage on it. But, you
know, I can't speak that that's the norm.
It it it happens. It all depends on
the insurance carrier. You know? Okay. So,
we'll put your company's website in the show
notes. So they actually reach out to you.
So if they have a cancer, they reach
out to your company directly.
Yes. And then
you would
guide them from there in terms of
samples,
how it happens,
the assessment, and then working with the the
doctor on the delivery.
A typical course of peptide therapy for cancer,
what are we looking at in terms of
IV infusions? You know, how many and at
what, dose frequency?
Yeah. You're looking at about a year to
16, you know, 14 months, 14 to 16
months worth of therapy, right? So and
it goes in stages. There are 4 courses
in a year,
and a course of treatment lasts anywhere from
21 to 30 days. So these peptides are
being administered over a 21 to 30 day
period. Right? And then there's usually a break
of about 4 to 6 weeks,
sometimes 8 weeks in between depend depends upon
where the cancer is in its staging. If
it's a pretty aggressive cancer, then there's no
breaks in between.
And it could be used with any,
conventional therapeutic modality. It's not affected negatively by
chemotherapeutics.
So,
we see,
very good complementary effects and much better effects
than you see with people who are receiving
chemotherapy,
right,
to to for them to be protected against
the chemo effects, but but as a hub
strategy, this can stand alone. But And, you
know So just for practical purposes, are we
talking about people with chemotherapy ports?
Yep. Yep. Yep. And then is the I've
is the infusions, are they continuous, or do
they come into a clinic and get some
more? Yeah. It's usually like the 3 time
a week infusion,
peptides. Right? And,
and then the doctor will send them home
with 2 injections that they do I'm So
it's a 5
out of 7 day regimen for for 21
to 30 days. Now if they, you know,
the reason why we have 30 days is
because some patients, take a little bit to
acclimate. You have to spread it out a
little bit longer, maybe drop the dose down
a little bit,
so that they act so that their bodies
respond because there's some patients that have more
robust responses than others. Right? And it's all
case it's all patient by patient. So you
can't,
you know, you can't really just, you know,
standardize
just the same thing for everyone. If one
patient might respond where you have to adjust,
the dosing down a little bit and spread
it out maybe by 24 to 72
hours. But, you know, doctors know our doctors
know,
when to do that. But for the most
part, it's a 21 to 30 day,
regime
4 times a year.
And if you were
to talk to a patient,
the patient says,
how does this work?
Is
it killing the cancer cells? Is it enhancing
the body's immune system to go kill the
cancer cells? What what are some of the
mechanisms that you're sure
are working with these products?
It's definitely cancer killing, tumor
killing, you know, those cells that are on
the tumor environment,
microenvironment.
It's,
direct targeting for hitting the cell the cancer
cells to get them to lice. It's also
reprogramming. So it's microediting and reprogramming
because these peptides have that
micro programming,
you know, immuno editing ability. So they don't
just have the direct,
immune defense effect. They also have the immune
editing effect.
So you get those 2 things working together
and, you know, as in a system,
especially when it's personalized to the patient's targets,
then you're getting these actions to work on
these different targets that are involved in that
cancer expression.
So that's where a lot of a lot
of the times, you know, you're gonna have
a better opportunity to to overcome
severe resistance and migration
by,
allowing,
you know, these peptides to work on the
different expressed targets because there's there's more than
one target involved in the cancer in the
cancer expression.
I'll have one final question for this,
half, and we're gonna have to take a
break. But it's a commercial question.
So
is a company like yours
and how it's personalized in your in a
sense, creating your market, the patients come to
you and you we you know, you work
on this together.
Is it kind of forever
going to be in this
realm? Or is this ultimately gonna go through
full FDA approval,
large trials,
the oncology
research networks,
all the intellectual property for all the different
peptides and in vitro diagnostics.
Kinda sketch this out commercially.
Well, you know, it would be the hope
that personalizations
and precision would go to that next level.
I don't see it happening, you know, within
the next 20 years or so because it's
so difficult. Right? Right. When you're talking about
an n of 1 design, you're talking about
you can't,
you can't group, you can't select the cancer
type and then you have, you have, we're
going to have 30 different expressed,
type of designs that, that have different, different
peptide sequence,
associations.
And and the
the NIH is not structured that way, so
neither is the FDA.
So it's like it's gonna take a while
for the a new a new paradigm shift
to happen in this in in the research
design, so to speak. Right?
But but what I do see is I
see a a lot more intelligent,
aspect in being able to know,
you know,
how to hit targets more intelligently.
Right? Mhmm. And and you know as well
as I do is that in, in the
conventional space, it's always about one signal, a
target like we see in these weight loss
drugs, for instance,
GLP, GIP,
that everybody is excited about this.
And what you wind up doing is you
wind up burning out those targets
with
chronic focus, and you find that they don't
work anymore, these drugs, the way they're supposed
to because of the fact that you're burning
these targets out. And it it's like spinning
your tires in place, basically.
And and,
and and, but but I do see that
changing where the molecular
expression that is more unique to the patient
instead of a stratified
design, you got more of a precision personalized
design happening. Whether or not it's going to
make a shift totally to n f 1,
I can't see that happening, like, within the
next 20 years. I really can't. Because it's
a it's a lot a lot of complicated
twists and turns.
I could be wrong about that, but we
are trying our best to participate in leading
the way
in using,
you know, a combination of human intelligence and
art and and, you know, artificial AI intelligence
and being in a responsible way to be
able to use the best of the tools
you can to get to that space of
better precision.
And that's what that's what we do is
we're focusing in on better precision.
And remind us the name of your company
again and website.
It's Neo 7 Bioscience.
All one word.
Neo 7 Bioscience. Well, I tell you, we
are having a fascinating,
conversation with doctor John Catanzaro.
He is leading,
this company,
Neo 7 Bioscience.
It's personalized.
So it's
yeah. We just is is not gonna,
at least at this point in time, be
in this large space of of clinical trials.
And we're learning so much about the fact
that probably each person's cancer, just like each
person is unique, their cancer is unique. We're
gonna take a break for our sponsor, and
then we're gonna be back. And we're gonna
cover these messenger RNA COVID 19 vaccines. I
know John has a lot to talk about,
a lot to say about them. So let's
get real. Let's get loud. On America loud
talk radio, this is the McCullough Report, and
I'm doctor Peter McCullough.
One of the biggest advances in nutraceuticals
and supplements
is healthy cell and the healthy cell line
is extensive.
I typically focus on the micro gel technology.
3 major products here, immune super boost,
the focus
and Recall,
and then the REM sleep supplement. Each one
of these is complimentary
and they can
have a role, I think, in the health
of your life each and every day. I
know they do. In my case,
many of you know
after COVID 19 twice, I spent almost the
entire year in 2022
with a upper respiratory tract illness. Now thankfully,
and I've been diligent
with the immune super boost in the morning,
followed by focus and energy,
and then in the evening time, the REM
sleep supplement, the Micro Gel Technology works and
boy, does it work fast. So go to
our website,
America Out Loud Talk Radio. Find the banner
bar for HealthiCell. Click on it and that'll
take you to the site to get a
discount
on your purchase of all HealthiCell products. So
let's get real, let's get loud on America
loud talk radio.
Maintaining a strong immune system has never been
more critical. Nutrition company, Healthy Cell, created immune
super boost to help you strengthen your immunity
unlike other supplements that don't work. Immune super
boost is not a pill. A gel you
swallow with ultra absorption of science backed nutrients
proven to support immunity, like vitamin c, d
3, zinc, elderberry, and echinacea.
Support your heart with concentrated
nutrients. Healthy Cell created heart and vascular health
to support cholesterol and blood pressure with co
q 10, vitamin k 2,
and soluble fiber. And Healthy Cell is not
a pill. It's a patent pending gel you
swallow. Get heart healthy. Go to healthycell.com
and use code out loud for 25%
off your first order. Healthycell.com.
Code out loud for 25%
off.
World class care from doctors you can trust,
all from the comfort of your home. That
is one wellness. Doctor Peter McCullough and his
team at the wellness company designed the One
Wellness membership to provide free monthly supplements and
unlimited telemedicine
access with doctors that share your values. Go
to out loud care dot com today and
use code out loud for 25%
off your 1st month of 1 wellness.
Is your gut a mess? 2 thirds of
Americans suffer because of gastrointestinal
issues, and I was one of them. That
is why we created a 3 step doctor
formulated
completely natural gut reboot system that you can
do at home in just minutes a day.
Go to chemicalfreebody.comforward/outloud
today. Get the Malcolm Healthy Gut Bundle,
reboot your gut and your energy, and save
20% on your first order.
Expert opinions, honest debate, and in-depth
investigations
are what you've come to expect
from America out loud dot news.
We don't shy away from speaking the truth
boldly and plainly.
All that's missing is the propaganda
that has infected legacy in social media.
Get the best of down and dirty, wholesome
American
speed.
Now is our time, my fellow Americans.
America Out Loud Loud Talk Radio,
liberty
and justice for all.
Let's get real. Let's get loud on America
loud talk radio. This is The McCullough Report.
And I'm doctor Peter McCullough, also rebroadcasting
on Courageous Discourse substack,
Fantastic
convo
with John Catanzaro.
I've learned so much
about how complicated the world is of can
is with cancer, John. And and you've
mentioned that the Pfizer and Moderna, the messenger
RNA vaccines, you know, have,
almost
so many design flaws
that molecular design flaws that are related to
their side effects,
and potentially autoimmune illness
in cancer.
Where are we
with industry
catching up to
the potential harms and diseases that messenger RNA
vaccines can cause?
No. I think that we are in a
pretty good space in being able to,
have what we call a immune a surveillance
and
and looking behind the curtain, so to speak,
of what's really happening in the molecular expressions.
Right?
Because, what what, what what most people need
to realize is that your body has an
intel,
molecular bio data points. And but these bio
data points need to be looked at
really careful. So, like, in other words, you
just can't leave one without the other. So
know, you just can't you you just can't
look at the DNA without looking at the,
you know, the RNA transcriptome expressions. You can't
just look at RNA without looking at the
proteome
expressions. You have to look at all of
these things together in correlative values so that
you can see what's amplified,
what what is under expressed, you know, how
how the environment is really responding to whatever
mechanism
of the salt there there might be. Right?
And and, you you know as well as
I do, Peter, that because I read your
pay you know, I've I've been reading a
lot of your papers.
And and thank you so much for your
contributions because it's, it's amazing.
It really it really helps to set
a lot of clarity out there. You know,
one of the first papers that actually came
out, which was the mRNA vaccine, the BNT
162 b 2. Right?
That pay that first paper that came out
when everybody was saying, well, no. I mean,
it's never gonna get back into the DNA.
The DNA is not gonna be corrupted. You
know what? That's that's totally false
because the m r Let me ask you.
Now we're talking about the paper. Marcus Alden
is the first author.
Yang de Marenis is the senior author. So
Malmo, Sweden,
human hepatoma cell line.
And that center part, the amplicon
the region that they could, you know, reliably
know was gonna be a good reporter region,
that 444
base pair. I thought the paper showed,
I think, convincingly,
it did get into
human DNA.
Now
are you telling me as an expert that
you think that's legit?
I know I know it's legit by the
expressions that we're actually seeing on the tran
on the RNA transcription
line. So we can see, like, for instance,
shifts and turns in, as I mentioned earlier,
DNA mismatch repair proteins.
We're actually seeing,
evidences
of, elevated destructive cytokine activity or toggle,
immune regulators that are faulty. You know, when
you're actually talking about this, this virtually affects
every protein in the body.
And, you know, particularly,
you know, in relation to accelerated cancers that
are associated with you could see tumor promoters
and 2 tumor suppressors totally out of whack
where they switch roles.
I mean, they when you you start switching
roles, it's not just about the cancer evolution
that's causing you to switch in the role.
When you have a destructive protein type of
transcript message that's coming out there with rogue
effects, then you wind up getting very poor
expressed,
activity of these these tumor proteins,
tumor suppressor,
tumor promoters
that actually are.
And and a lot of the times, we're
seeing relationships with, you know, the mRNA getting
back into
get into bad messaging, back into splice
splice variant type activity that happens with the
DNA.
So,
so there's no doubt in my mind we're
seeing,
we're actually seeing mRNA,
being reintegrated
into DNA.
And then as you know, this propagates over,
you know, the cell progeny. So with each
cell progeny that happens, you know, you have
you're you're having these billions of copies that
are happening, you know, with new cellular,
with new cellular colonies forming. Well, now let
now let me ask you, John. Do you
think the entire
code let's say Pfizer,
the code I don't know if it's, like,
34 100 base pairs or 4000 base pairs.
Do you think the entire code is reverse
transcribed into into human DNA?
I don't know about the entire code itself,
though the entire code can be.
It it could be actually segments of the
code.
So when we're talking about segments of a
code, then you're talking about, you know,
a segment of a code can actually create
a pro
an an a variant protein switch, and we
you have no idea what that a variant
protein switch would be unless you're looking at
the data expression as a whole.
So we what you can act for instance,
mitochondrial proteins on the complex, mitochondrial
complex proteins, you know, there's a complex the
complex one through, you know, 1 the complex
1 through 4. What we're seeing is complex
1, 2, and 3,
effects of,
pro inflammatory
activity associated with the COVID RNA.
So you actually wind up seeing a very,
loose complex formation
in molecular simulations
to where the complexes are not tightly,
tightly knit together. They become fractured and unbound.
And and when you're talking about anything in
the complex of a mitochondria,
you know, creating that type of a,
signaling flaw, you you're talking about the electronic
transport chain be being affected. You're talking about
bad packing
of proteins being affected all the way around.
The mitochondria,
dysfunction happens.
The mitophagy
happens with an accelerated
rate, and then, you know,
and then the cells begin to die
very quickly.
Right? Oh my lord. There's there's
there's there's thousands of mitochondria in the same
cell.
So, you know, it it is not just
like 1 or 2. So you gotta you
have a lot you have a lot of
mitochondrial interface. And if you if you have
if you have a a a very strong,
bad signaling,
complex, you're going to have, mitochondrial
overheating and destruction happening pretty rapidly.
And and a lot of these a lot
of times what you're seeing with mRNA splice
segments
affecting this is that it creates that accelerated,
aberrant,
type activity.
Now could you see that
with no genomic integration, just the Pfizer, Moderna,
messenger RNA,
moving in and out of cells?
Yes. I see that. Of course, you can.
Okay. Well,
with with an injection,
people have have tried to, you know, get
their heads around this. Is does every cell
encounter
the messenger RNA as every cell, or is
it is it gonna be a mosaic, just
some cells or or some few cells? Yeah.
It depends on the susceptibility
of the of the individual.
So in other words, the, you know, what
I call the
the intelligence center of the immune system, which
is found on chromosome number 6, is your
HLA center, which is actually allowing for the
prediction of susceptibility, compatibility, adaptability. Right? So remember
when COVID hit, there was a lot of
we we had the opportunity
opportunity to develop a epitope strategy that hit
the viral expressions on 8 different targets. And
we we put that paper out back in
20,
2021
or 2022.
And it was after the fact. We we
we worked on a mutant strain of SARS
CoV 2. So we we knew that whatever
we were gonna do there, we would have
the infants. We had a complete 90 it
was a 99.5
eradication of the virus
with actual recovery and regenerative activity of damaged
tissue.
So so what you wind up seeing is
is that, like you're saying, it could be
a mosaic
depending upon the susceptibility of the individual.
Okay? If they have a very strong susceptibility
to they're going to have a lot more
destructive influence in their body. So it could
actually hit their kidneys, it could hit their,
you know, their heart muscle, it could hit
their brain tissue, in which you've actually seen
some significant,
correlative,
activity with various type of fibrous activity that's
occurred
because Do you think it's susceptibility
that explains
why some people are injured and others aren't?
And why
different organ systems? Do you think it's more
a And I think number 2, if we
have a a very high,
susceptibility,
HLA pattern, then yes. I mean, it's like
it's similar to what you see with an
organ rejection.
So if you're actually seeing an organ rejection,
right,
you're
you're going to have a very vigorous response
in destructing destroying an organ that's transplanted in
it if it's not a good match. So
it's the it's it's kinda using that,
the rejection system. The HOA system is like
basically was is known as the rejection system
that allows for tissue matching,
and but now it's a lot more than
that. It's actually the driving force of of,
of immune compatibilities
and susceptibilities.
So what we can see is that you
can correlate this with various type of you
know, like if a person is more susceptible
to a specific viral strain
than, than, you know, some, some other person
that has a very strong, a strong resistance
against it. You know, certain HLA patterns demonstrate
good resistance
or
the the contrary. They could be susceptible, highly
susceptible.
Do do you think spike protein,
produced from the messenger RNA vaccines and frame
shifted proteins,
do you think they're expressed on the cell
surface?
I I think that they,
I think that they are,
they can be expressed in various type of,
ways. For instance, if we're talking about the
the corruption of the of the cell signaling
in the nucleus,
and and we're getting, you know and and
it may not necessarily hit the 1st cell
cycle. Like, in other words, you're looking at
the first cells. They may not be necessarily
hitting that, but then you have an uptake
of another systemic,
related cell, and it starts to generate,
you know, this activity. Then all of a
sudden, you're starting to see a a a
cumulative effect of propagated
bad, you know, bad cell signaling across the
board, which then, you know, in a lot
of cases, like in the cancer case, when
you have tumors,
associated proteins, tumor specific proteins,
the mRNA could be drivers of these TA
TSA TAA relationships,
right? Because of the fact they're corrupting the
protein expressions. And then you're gonna find that
this, you're gonna find that the, the, the
cell is no longer expressing a healthy,
cell,
membrane receptivity. It's it's showing dysfunctional proteins on
the surface. Yeah. I mean In that in
that way, you know, it may not necessarily
be direct, but it would be indirect,
pending upon
the, you know, the cell cycling. Because as
you know, the mRNA
will definitely,
get back to more like I was saying
earlier, it hits the the WNT notch system
sideways. It's not the only system, but it
also hits DNA mismatch repair system.
And and then we start seeing some pretty
funky things happen. Mhmm.
Well, listen. We only have about a minute
left, but I have to ask you. Give
us some hope. Do you think
the vaccine injured have an opportunity for this
new paradigm of personalization,
proteomics,
urine and blood,
and then tailored
protein therapy or peptide therapy?
Absolutely. Because these strategies that are n of
1 designed personalized. Right? They're gonna get directly
to those bad, expressed targets. You know, if
you have what we call excessive cyto cytokine,
enhancement that you don't wanna see, and you
have a pro inflammatory destructive posture, if that's
not mitigated
appropriately by, you know, using the right,
peptide,
assembly,
you're you're going you're you're not gonna be
able to stop that activity. So
looking under the looking under the hood or
behind the curtain gives us the ability to
know how to toggle those switches better and
how to hit them directly. So we've been
actually seeing
very amazing
results with pro inflammatory
posturing and
mitigating against it and people recovering.
So there is there is hope with personalizations
for sure. Wow. So exciting. We're gonna have
to leave it here. Doctor John Catanzano,
CEO and founder
of Neo 7 Bioscience.
We're talking
personalized
proteomic,
in vitro diagnostics,
coming up with a plan, cancer, vaccine, injury,
and that administration
of
peptides
that,
that are therapeutic, that are disease mitigating, potentially
curative.
John, thank you so much for joining us
on the show. Thank you, Peter. It was
an honor to be on your show, and,
thank you so much for all the contributions.
I'm I'm a fan of yours very much
so. So thank you. Thank you. Let's get
real. Let's get loud on America Out Loud
Talk Radio. This is a McCullough Report and
courageous discourse substack.